The Hyperfine Swoop is a genuinely different piece of technology than any conventional MRI system in the market. Rather than positioning a patient inside a room-sized shielded bore and operating a superconducting magnet at cryogenic temperature, the Swoop is a portable, battery-operable, low-field MRI unit that can be wheeled to the patient's bedside, operated by existing clinical staff without specialized MRI technologist training, and powered from a standard 110-volt hospital outlet. The implications for certain clinical settings are significant, and the financing approach reflects the platform's distinct total project economics.
The Swoop operates at 64 millitesla, which is far below the 1.5T and 3T field strengths that dominate conventional clinical MRI. That low field strength produces images with substantially less signal-to-noise ratio than a high-field system. For routine diagnostic radiology where image quality drives clinical decisions, the Swoop is not a substitute for a conventional system. For the clinical applications it was designed for, primarily bedside neuro monitoring in ICU and critical care settings, its ability to bring imaging to the patient rather than transporting a critically ill patient to the scanner room is a practical advantage that a conventional MRI cannot match regardless of field strength.
We finance the Hyperfine Swoop for hospitals, academic medical centers, and clinical programs that have evaluated the system for its specific intended use case. The acquisition cost is substantially lower than conventional MRI systems, the siting requirements are minimal, and there are no cryogen or chiller costs. For more context on the portable MRI category broadly, our page on portable MRI financing covers the options available in this growing segment.
The Hyperfine Swoop: How It Works and What It Is For
The Hyperfine Swoop is FDA-cleared for clinical use in the United States and has been deployed at academic medical centers, community hospitals, and critical care facilities that evaluated it for bedside neuroimaging. Its primary use case is monitoring patients in neuro ICUs for conditions such as hydrocephalus, intracranial hemorrhage, and post-surgical changes, where repeated imaging is needed but transferring a critically ill patient to the radiology suite poses real risk and logistical burden.
The system's low-field images are sufficient for detecting major intracranial events. For subtle parenchymal abnormalities or advanced neuroimaging protocols, the resolution and signal quality are not equivalent to a high-field system, and the clinical workflow at any site using the Swoop should reflect this reality in its imaging indication protocols. Hyperfine has been transparent about this distinction, and practices that have adopted the system have done so with clear eyes about the clinical applications it serves.
From an infrastructure standpoint, the Swoop eliminates nearly every conventional MRI siting requirement. No RF shielding room is required beyond basic environmental management, no cryogens are involved, no specialized power supply is needed beyond standard hospital power, and no dedicated technologist certification is required beyond the training Hyperfine provides. This means the total project cost is close to the system purchase price itself, with minimal ancillary capital investment required. Compare this to a conventional superconducting MRI where siting and infrastructure can represent 30 to 50 percent of total project cost.
Who Is Buying the Hyperfine Swoop
The primary buyers of the Hyperfine Swoop have been hospital systems and academic medical centers evaluating it for specific critical care and neurology applications. Neuro ICUs in particular have been the clinical home for the Swoop at sites where it has been deployed, given the specific problem it solves: reducing the transport burden for the sickest patients while maintaining imaging access.
Neurology clinics and neuroscience programs that treat a high volume of ICU-level patients, or that serve patient populations with significant mobility or transport limitations, are the natural evaluators of the Swoop outside the hospital setting. Our page on neurology clinic financing covers the broader MRI financing landscape for neurology-focused practices.
Academic medical centers with clinical research programs have also acquired Swoop systems for research studies evaluating point-of-care MRI in various settings, including stroke care and pediatric neurology. For these research applications, the financing structure may differ from a standard commercial equipment transaction. Our research lab imaging financing page covers how research-oriented acquisitions are handled.
Mobile imaging providers evaluating the Swoop as a true bedside or point-of-care service offering may find it opens clinical deployment contexts that conventional mobile MRI trailers cannot serve. Our page on mobile imaging provider financing covers the broader mobile MRI market context.
Financing the Hyperfine Swoop
The Hyperfine Swoop's acquisition price is a fraction of a conventional superconducting MRI system. This places most Swoop transactions well within our application-only program, which requires a credit application and the vendor quote without a full financial package. Most hospital systems and established clinical practices will qualify for straightforward approval at this price point.
We structure equipment loans and equipment leases for Swoop acquisitions with terms from 24 to 60 months. Given the system's lower acquisition cost, even 36-month terms produce manageable monthly payments for most buyers. An operating lease may suit programs that want to evaluate the clinical utility before committing to ownership, with the option to upgrade if Hyperfine releases a subsequent generation with improved performance.
For hospital systems purchasing multiple units for deployment across several floors or facilities, we can structure a fleet transaction that covers the batch purchase as a single loan, simplifying the administration and potentially producing more favorable aggregate terms than individual unit financing.
Context: Where Swoop Fits in the Broader MRI Landscape
The Hyperfine Swoop is part of a broader shift in point-of-care imaging that includes other low-field and portable MRI development. As a buyer considering the Swoop, it is useful to understand where it sits relative to other options in the portable and low-field MRI category. Conventional mobile MRI delivered via a trailer-mounted superconducting system is a separate product class entirely, representing a full high-field scanner made mobile rather than a purpose-built point-of-care device. Those systems are covered in our mobile MRI financing page.
For practices that need full diagnostic imaging capability at multiple sites, a mobile high-field MRI on a trailer is still the appropriate solution for general radiology volume. The Swoop fills a different gap specifically for settings where taking the patient to the scanner is not feasible or advisable.
Comparing the Swoop to a low-field dedicated extremity system like an Esaote O-scan is also not an accurate comparison. The Esaote serves musculoskeletal imaging in an outpatient orthopedic setting. The Swoop serves neuro monitoring in critical care. Their imaging physics overlap at the low-field end, but their clinical applications are almost entirely distinct. Our page on Esaote financing covers the dedicated MSK imaging segment separately.
Hyperfine Swoop Financing Questions
- Is the Hyperfine Swoop FDA-cleared for clinical use, or is it only for research? The Swoop is FDA-cleared for clinical use and has been deployed in clinical settings at multiple major medical centers in the United States. The imaging indications supported by the clearance are specific to the system's capability, and sites should develop protocols that align with the clearance language.
- Can we finance multiple Swoop units at once for deployment across several ICUs? Yes. Fleet financing for multiple units under a single transaction is available. We size the loan to the total purchase price and structure a single monthly payment. This simplifies administration compared to managing individual loans for each unit.
- Does the Swoop require a service contract, and can that be financed? Hyperfine offers service and maintenance programs for the Swoop. Service contracts are operating expenses and are typically not included in equipment financing, but they belong in the total cost of ownership model when evaluating the system.
- What happens to the Swoop's residual value at the end of a lease? Residual value for the Swoop reflects the secondary market for used units, which is early stage given the platform's recent introduction. Operating lease terms for Hyperfine systems are structured with conservative residual assumptions. This affects the monthly payment calculation compared to a system with a more established secondary market.
Finance Your Hyperfine Swoop Purchase
If your facility is ready to acquire a Hyperfine Swoop for bedside neuroimaging or a multi-unit deployment across critical care areas, share the purchase details and we will structure the financing. Most Swoop transactions are straightforward to underwrite and can close quickly given the system's favorable price point relative to our standard review thresholds.